RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.

By F. Danhier, Aude Le Breton, V. Préat. Molecular Pharmaceutics, 2012

898 citations recorded by the source corpus.

Subfields: Immunology, Immunology and Allergy, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1147a63fcd39ed3760dd78b3bb70e8990c55528f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Fabian Kiessling
2. Peng Liu
3. Jingchen Zhang
4. Guiliang Chen
5. T. Lammers

Citations in the corpus

• A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives (2022, background): “, iRGD [27], iNGR [28]), small molecules (folic acid [29]), and carbohydrates (e.”
• Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “A prototypic strategy for active vascular targeting is to functionalize nanocarriers with the Arg-Gly-Asp (RGD) peptide [189].”
• Nanomedicine in cancer therapy (2023, background): “92,261 267 It is noteworthy that the steric conformation of RGD-based peptides can considerably affect their targeting ef fi ciency and pharmacokinetic properties.”